CDC42-A promising immune-related target in glioma

Tao Jiang1,2, Xianwei Wang1, Jiaming Huang1

  • 1Department of Neurosurgery, The Dalian Municipal Central Hospital, Dalian, China.

PubMed

Insights

Cell division cycle 42 (CDC42) is overactivated in glioma, correlating with poor prognosis and higher tumor malignancy. Targeting CDC42 may offer a new avenue for glioma immunotherapy.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glioma is a severe central nervous system neoplasm with poor prognosis.
  • Overactivation of cell division cycle 42 (CDC42), a polarity-regulating GTPase, is linked to increased tumor malignancy in various cancers.

Purpose of the Study:

  • To investigate the role and prognostic significance of CDC42 expression in glioma.
  • To explore the association of CDC42 with clinical features, biological functions, and immune infiltration in glioma.

Main Methods:

  • Analysis of CDC42 RNA-seq and protein expression data from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases.
  • Differential expression analysis, survival analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and immune infiltration analysis were performed.
  • Correlation analysis with clinical parameters, including WHO grade, IDH1 status, MGMT methylation, and 1p19q codeletion.

Main Results:

  • CDC42 expression was significantly upregulated in glioma tissues compared to normal controls.
  • Elevated CDC42 levels were strongly associated with poor prognosis and adverse clinical indicators (higher WHO grade, wild-type IDH1, unmethylated MGMT, non-codeleted 1p19q).
  • CDC42 enrichment correlated with immune and inflammatory responses, immune checkpoints, and regulatory T cell markers (CD4, CD25, CD127).

Conclusions:

  • CDC42 is a potential biomarker for predicting poor prognosis in glioma.
  • CDC42 plays a role in regulating the tumor immune microenvironment in glioma.
  • CDC42 represents a promising therapeutic target for glioma immunotherapy.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K